Integra LifeSciences
IART
264 hedge funds and large institutions have $5.11B invested in Integra LifeSciences in 2021 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 95 increasing their positions, 76 reducing their positions, and 29 closing their positions.
34% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 29
25% more repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 76
3% more funds holding
Funds holding: 256 → 264 (+8)
0.97% more ownership
Funds ownership: 87.5% → 88.47% (+0.97%)
0% more capital invested
Capital invested by funds: $5.1B → $5.11B (+$4.75M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
+$14.8M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
+$12.5M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$11.9M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$11.6M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$11.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$17.9M |
| 2 |
Millennium Management
New York
|
-$14.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.63M |
| 4 |
MPAM
Monarch Partners Asset Management
Boston,
Massachusetts
|
-$5.71M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$5.49M |
IART Hedge Fund Activity: Q2 2021 in Review
264 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q2 2021, worth a combined $5.11B — up 0.09% from $5.1B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new IART positions and 29 closed out — a net gain of 10 holders — while 95 added to existing stakes and 76 trimmed.
The largest buyer was Eaton Vance Management, adding an estimated $14.8M. The largest seller was Invesco, cutting an estimated $17.9M.
- 264 institutional investors held Integra LifeSciences (IART) as of Q2 2021, up from 256 in Q1 2021.
- Funds reported $5.11B of Integra LifeSciences stock for Q2 2021, up 0.09% quarter-over-quarter.
- 39 funds opened new Integra LifeSciences positions in Q2 2021 and 29 closed out, a net change of +10 holders.
- The largest Integra LifeSciences buyer in Q2 2021 was Eaton Vance Management, an estimated $14.8M added.
- The largest Integra LifeSciences seller in Q2 2021 was Invesco, an estimated $17.9M sold.
Based on aggregated 13F filings for Q2 2021.